XNCR

Xencor, Inc.

19.54 USD
+0.17 (+0.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Xencor, Inc. stock is down -20.24% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 June’s closed higher than May. 100% of analysts rate it a buy.

About Xencor, Inc.

Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.

  • Raymond James
    Fri Jun 14, 11:38
    buy
    confirm
  • BMO Capital
    Fri Jun 14, 11:18
    buy
    confirm
  • RBC Capital
    Fri Jun 14, 10:09
    buy
    confirm